Abstract:ObjectivesThis study aimed to investigate the impact of molecular classification and other oncogenes including PTEN, KRAS and PIK3CA gene mutation on fertility preserving treatment outcome in patients with endometrial cancer and endometrial atypical hyperplasia (EC/EAH).MethodsA total of 135 EC/EAH patients receiving fertility preserving treatment and molecular classification were retrospectively reviewed. The distribution of the four types of molecular classification was described. The impact of MMRd and NSMP, as well as PTEN, KRAS and PIK3CA gene mutation on treatment outcome was also analyzed.ResultsMost of the patients were classified as non-specific molecular profile (NSMP) (117/135, 86.7%), while 14 patients (10.4%) were mismatch repair deficient (MMRd), 1 patient (0.7%) was POLE-mutated, and 3 patients (2.2%) were p53 abnormal. Patients with NSMP and MMRd achieved similar cumulative CR rates at 16 weeks, 32 weeks, and 48 weeks of treatment in either EC or EAH patients. Patients harboring pathogenic or likely pathogenic PTEN mutations (PTENmut-P/LP) achieved lower cumulative 32-week CR rate (22/47, 46.8% PTENmut-P/LP vs 50/74, 67.6% PTEN-others; P=.023; OR 0.422 95%CI 0.199–0.896). Kaplan-Meier analysis presented similar results. Univariate analysis showed that insulin-resistance and PTENmut-P/LP were related to poor treatment outcomes. In multivariate analysis, insulin-resistance (HR 0.435; 95%CI 0.269–0.702; P=0.001) and PTENmut-P/LP (HR 0.535; 95%CI=0.324–0.885; P=0.015) remained independent negative predictors of fertility preserving outcomes.ConclusionsPTEN mutation is identified as poor prognostic factor in patients receiving fertility preserving treatment, with a lower CR rate and longer treatment duration. MMRd patients achieved similar outcomes with NSMP. Molecular profiles might guide fertility preserving treatment in prognosis and treatment decisions.

O033/#702 Pten and Molecular Classification As Prognostic Factors to Predict Fertility Preserving Treatment Outcomes in Patients with Endometrial Cancer and Endometrial Atypical Hyperplasia